default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

GC Pharma’s high-content vitamin becomes blockbuster drug

Lee Han-soo  Published 2018.01.09  11:49  Updated 2018.01.09 11:49

공유
default_news_ad2

GC Pharma said Monday that B-Max, a high-content vitamin, has become a blockbuster drug as its annual sales exceeded 10 billion won ($9.3 million) last year.

In the Korean pharmaceutical industry, if the annual sale of a single item exceeds 10 billion won, it is classified as a blockbuster drug. The blockbuster drug designation comes five years after the company released B-Max in 2012.

“Such a feat is meaningful as the company did not place any public advertising to increase brand recognition and sales,” the company said in a statement. “It is also noteworthy that GC Pharma, which is known as a flagship business for blood products and vaccines, has developed a general drug blockbuster.”

Based on this success, GC pharma plans to expand its business to the general pharmaceutical market. The company is planning to integrate its existing OTC headquarters into its CHC (Consumer Health Care) headquarters to diversify its distribution channels and expand product range.

“The company plans to come up with a mid- to long-term strategy to reach consumers directly beyond the existing limited channels through the establishment of general distribution and online infrastructure,” a company official said.

The company will devote efforts to making more blockbuster drugs, he added.

B-Max consists of four lineups – Active, Gold, Ace, and Liquid.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch